ZP
PLRX icon

Zimmer Partners’s Pliant Therapeutics PLRX Stock Holding History

Zimmer Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-85,741
Closed -$2.78M – 149
2020
Q2 		$2.78M Buy
+85,741
New +$2.28M 0.04% 89

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Zimmer Partners's PLRX Position: Q3 2020 in Review

Zimmer Partners sold out of Pliant Therapeutics (PLRX) in Q3 2020, closing a stake of 85,741 shares — an estimated $2.78M sold.

Zimmer Partners first reported a position in PLRX in Q2 2020 and held it in 1 quarter. The position peaked at $2.78M in Q2 2020. 55 funds tracked by Wall St. Rank hold PLRX as of Q3 2020.

  • Zimmer Partners reported no remaining Pliant Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Zimmer Partners sold 85,741 Pliant Therapeutics shares in Q3 2020, an estimated $2.78M.
  • Zimmer Partners first reported a position in Pliant Therapeutics in Q2 2020 and held it in 1 quarter.
  • Zimmer Partners's Pliant Therapeutics position peaked at $2.78M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2020.

Based on Zimmer Partners's 13F filing for Q3 2020, filed 16 Nov 2020.